Comparison of SUV Using SPECT/CT Between Grave's Disease Patients and Normal Humans
Comparison of Standardized Update Value Using Single-photo Emission Computed Tomography and Computed Tomography Between Grave's Disease (Hyperthyroidism) Patients and Normal Humans
1 other identifier
observational
100
1 country
9
Brief Summary
The purpose of this study is to find out the capacity of standardized uptake value (SUV) using single-photo emission computed tomography and computed tomography (SPECT/CT) in diagnosing Grave's Disease (hyperthyroidism).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2016
Shorter than P25 for all trials
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2016
CompletedFirst Submitted
Initial submission to the registry
May 9, 2016
CompletedFirst Posted
Study publicly available on registry
May 13, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2017
CompletedMay 13, 2016
May 1, 2016
3 months
May 9, 2016
May 11, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
The thyroid imaging of GD patients and normal humans by SPECT/CT
For GD patients and normal healthy volunteers, we will get the data of thyroid fusion imaging by giving them a SPECT/CT check at subject enrollment.
a single point in time, at subject enrollment
The SUV values of GD patients and normal humans provided by Q.Metrix
The data of thyroid fusion imaging will be processed by the software, Q.Metrix, which can get the accurate SUV by compensating for photon absorption within the body, removing scattered radiation and etc.
a single point in time, at subject enrollment
Study Arms (2)
Hyperthyroidism
Those with Grave's Disease(GD,Hyperthyroidism),with lower TSH, and higher FT3, FT4.
Health Humans
Those humans who are healthy, without GD, without any treatment, with normal TSH, FT3, FT4.
Eligibility Criteria
As for GD patients, the study samples will be chosen from the patients in every medical center which participates in this study. And they will be chosen before their treatment. For the normal humans, they are healthy volunteers without thyroid disease.
You may qualify if:
- certainly diagnosed with GD
- no treatment
- sign a informed consent
You may not qualify if:
- Inflammatory Hyperthyroidism
- Secondary Hyperthyroidism (since of medicine, thyrotrophs neoplasms and etc)
- Can not finish the check of SPECT/CT
- Refuse to sign a informed consent
- For Group of Normal Humans:
- without GD
- Adult
- sign a reformed consent
- Without normal values of TSH, FT3, FT4
- Can not finish the check of SPECT/CT
- Failed to sign a reformed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- West China Hospitallead
- Beijing Tongren Hospitalcollaborator
- Guangzhou Panyu Central Hospitalcollaborator
- Hebei General Hospitalcollaborator
- Air Force Military Medical University, Chinacollaborator
- Zhejiang Cancer Hospitalcollaborator
- The First Affiliated Hospital of Zhengzhou Universitycollaborator
- Tianjin Medical University General Hospitalcollaborator
Study Sites (9)
Beijing Tongren Hospital
Beijing, Beijing Municipality, 100000, China
Guangzhou Panyu Central Hospital
Guangzhou, Guangdong, 510000, China
Hebei General Hospital
Shijiazhuang, Hebei, 050000, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450000, China
The People's Hospital of Inner Mongolia Autonomous Region
Hohhot, Inner Mongolia, 010000, China
Fourth Military Medical Universit
Xi’an, Shanxi, 710000, China
West China Hospital
Chengdu, Sichuan, 610000, China
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300000, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310000, China
Related Publications (1)
Bailey DL, Willowson KP. An evidence-based review of quantitative SPECT imaging and potential clinical applications. J Nucl Med. 2013 Jan;54(1):83-9. doi: 10.2967/jnumed.112.111476.
PMID: 23283563BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Lin Li, Master
West China Hospital of Sichuan University, Department of Nuclear Medicine
- STUDY DIRECTOR
Xiaohong Ou, Ph.D
West China Hospital of Sichuan University, Department of Nuclear Medicine
- PRINCIPAL INVESTIGATOR
Yahao Li, Bachelor
West China Hospital of Sichuan University, Department of Nuclear Medicine
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Technologist, a graduated student of Department of Nuclear Medicine
Study Record Dates
First Submitted
May 9, 2016
First Posted
May 13, 2016
Study Start
May 1, 2016
Primary Completion
August 1, 2016
Study Completion
January 1, 2017
Last Updated
May 13, 2016
Record last verified: 2016-05
Data Sharing
- IPD Sharing
- Will share
The data of the subjects will be shared including gender, age, values of SUV, TSH, FT3, FT4 and other relative records. The information will not be shared until the study is completed and the article is published. Anyone who wants to get the data should send an e-mail to Li, with reasons for needing these data. E-mail address: 617381606@qq.com